Tacalyx appoints Dr. Klaus Schollmeier as Chairman of the Board
A pharma and biotech executive and adviser with more than 30 years of experience in R&D, marketing and general management.
Tacalyx has appointed Dr. Klaus Schollmeier as Chairman of its Board of Directors.
Dr. Schollmeier has been a senior executive and adviser to the pharmaceutical and biotech industries for more than 30 years, with leadership experience in R&D, marketing and general management. He is managing director of a consulting and investment firm and chairs the boards of several European biotechnology companies.
